Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diclofop is a synthetic small molecule herbicide belonging to the aryloxyphenoxypropionic acid class. It acts as a selective post-emergence herbicide primarily used for controlling grass weeds in cereal crops such as wheat and barley. Diclofop functions by inhibiting the enzyme acetyl-CoA carboxylase (ACCase), which is essential for fatty acid biosynthesis in plants. This inhibition disrupts lipid synthesis and leads to plant death. Diclofop is not approved for pharmaceutical use in humans or animals and has no known therapeutic indications[3][5]. It is considered hazardous upon exposure and should be handled with caution due to potential health risks including skin/eye irritation and neurotoxicity at high doses[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diclofop.